-
1
The HORIZON study evaluated the Hydrus Microstent's safety and efficacy.
-
2
80% patient follow-up over five years.
-
3
77.2% achieved significant IOP reduction at 24 months.
-
4
59% remained medication-free at five years.
-
5
Hydrus reduces postoperative IOP spikes.
-
6
Fewer patients require subsequent glaucoma surgeries.
-
7
Results emphasize long-term data in device studies.
-
8
Study presents significant reliability and data robustness.
Original Source(s)
Related Content
Focus on Focus A-Eye
The Focus A-Eye Summit in Denver, CO (May 2, 2026) will unite ophthalmology experts to advance AI applications
April 24, 2026
-
1 min
Free Vision Care Clinic for Vulnerable Groups in UK
Partnership provides eye tests and glasses to people excluded from NHS services.
April 24, 2026
-
2 min
Beyond IOP
Systematic review examines how lifestyle modifications could be used as complementary IOP-lowering strategies for glaucoma patients
April 24, 2026
-
3 min
